First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea

Abstract

Background & nbsp;Benzodiazepines are frequently prescribed during pregnancy; however, evidence about possible teratogenicity is equivocal. We aimed to evaluate the association between first-trimester benzodiazepine use and the risk of major congenital malformations.& nbsp;Methods and findings & nbsp;Using Korea's nationwide healthcare database, we conducted a population-based cohort study of women who gave birth during 2011 to 2018 and their live-born infants. The exposure was defined as one or more benzodiazepine prescriptions during the first trimester. We determined the relative risks (RRs) and confidence intervals (CIs) of overall congenital malformations and 12 types of organ-specific malformations. Infants were followed from birth to death or 31 December 2019, whichever came first (up to 8 years of age). Propensity score fine stratification was employed to control for 45 potential confounders. Among a total of 3,094,227 pregnancies, 40,846 (1.3%) were exposed to benzodiazepines during the first trimester (mean [SD] age, 32.4 [4.1] years). The absolute risk of overall malformations was 65.3 per 1,000 pregnancies exposed to benzodiazepines versus 51.4 per 1,000 unexposed pregnancies. The adjusted RR was 1.09 (95% CI 1.05 to 1.13, p < 0.001) for overall malformations and 1.15 (1.10 to 1.21, p < 0.001) for heart defects. Based on mean daily lorazepam-equivalent doses, the adjusted RRs for overall malformations and heart defects were 1.05 (0.99 to 1.12, p = 0.077) and 1.12 (1.04 to 1.21, p = 0.004) for < 1 mg/day and 1.26 (1.17 to 1.36, p < 0.001) and 1.31 (1.19 to 1.45, p < 0.001) for > 2.5 mg/day doses, respectively, suggesting a dose-response relationship. A small but significant increase in risk for overall and heart defects was detected with several specific agents (range of adjusted RRs: 1.08 to 2.43). The findings were robust across all sensitivity analyses, and negative control analyses revealed a null association. Study limitations include possible exposure misclassification, residual confounding, and restriction to live births.& nbsp;Conclusions & nbsp;In this large nationwide cohort study, we found that first-trimester benzodiazepine exposure was associated with a small increased risk of overall malformations and heart defects, particularly at the higher daily dose. The absolute risks and population attributable fractions were modest. The benefits of benzodiazepines for their major indications must be considered despite the potential risks; if their use is necessary, the lowest effective dosage should be prescribed to minimize the risk.& nbsp;Author summary & nbsp;Why was this study done?& nbsp;Anxiety and insomnia are common during pregnancy, and benzodiazepines are frequently prescribed for managing these conditions.& nbsp;The safety of benzodiazepines during pregnancy remains uncertain, as their evidence from epidemiological studies is limited and conflicting.& nbsp;What did the researchers do and find?& nbsp;In this large nationwide cohort study of more than 3 million pregnancies, we found a small increased risk of overall and heart defects associated with first-trimester benzodiazepine use.& nbsp;The risk of overall and heart defects was slightly increased at the high daily dose group, suggesting the dose-response relationship. A small but significant increased risk for overall and heart defects was detected with several specific benzodiazepines & nbsp;What do these findings mean?& nbsp;The findings suggest that, although small, the potential risks should be evaluated against the efficacy of benzodiazepines and the lowest effective dosage should be recommended when prescribed in early pregnancy.& nbsp;The increased risk for congenital malformations observed with several specific agents should be carefully monitored in future research as a potential safety signal.